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Abstract
Diabetes mellitus is a chronic disease that is associated with serious health problems and high costs. According 
to estimates gained from nationally representative health surveys conducted by the Robert Koch Institute (RKI), 4.6 
million adults aged 18 to 79 suffer from diabetes in Germany. In addition, around 1.3 million adults have undetected 
diabetes. A surveillance system is currently being established at the RKI in order to gather the data sources available 
on diabetes in Germany and to provide reliable and comparable findings on time trends covering the frequency, 
progress of treatment, prevention and care of the disease. Next to identifying trends, diabetes surveillance also 
needs to detect differences in epidemiology that are related to social status or geographic region. Diabetes surveillance 
at the RKI is being undertaken in close cooperation with stakeholders involved in science, health-care provision, 
health policy and health-system self-governance. Furthermore, its progress is accompanied by an interdisciplinary 
scientific advisory board.
Diabetes surveillance involves the following key elements: 1) the development of a research-based conceptual 
framework that uses indicators to appropriately measure developments in the disease; 2) the establishment of 
standards for the use of existing data sources and the identification of barriers to data usage and gaps in the data; 
and 3) the implementation of focused health reporting that is geared towards the target group. In addition to policy 
consultations, diabetes surveillance must guarantee the provision of timely and continuous information to the 
public together with the Federal Agency for Health Education. The implementation of a diabetes surveillance in 
Germany should act as a model and serve as a basis with which to establish the surveillance of other non-
communicable diseases.
In principle, indicator-based diabetes monitoring at the population level can be viewed as providing the body for 
evidence-based policy consultation and focused health policy. In turn, this should enable the implementation of 
effective disease prevention measures and high-quality care for all groups within the population.
 DIABETES MELLITUS · HEALTH MONITORING · DIABETES SURVEILLANCE · HEALTH REPORTING · PREVENTION 
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1. Background and aims
Diabetes mellitus covers a group of diseases that are 
characterised by a permanent increase in blood glucose 
concentrations. Diabetes is caused by a disorder of insu-
lin secretion, reduced insulin sensitivity (insulin resis-
tance) or a combination of both factors. There are two 
main forms of the disease: type 1 diabetes mellitus is an 
autoimmune disease caused by impaired insulin secre-
tion resulting from the destruction of islet cells in the 
pancreas. By contrast, insulin resistance is the main fac-
tor in type 2 diabetes mellitus. Alongside a genetic pre-
disposition, lifestyle factors play a crucial role in devel-
oping type 2 diabetes. In Germany, estimates from 
nationally representative health surveys conducted by 
the Robert Koch Institute (RKI) demonstrate that 4.6 
million adults aged 18 to 79 have diabetes. In addition, 
around 1.3 million adults have undetected diabetes [1]. 
Current figures on the prevalence of diabetes in Germa-
ny as well as regional frequency distributions can be 
found in a separate article in this issue [2].
According to the latest research, approximately 90% 
of cases of the disease are type 2 diabetes mellitus. Men 
generally demonstrate a higher lifetime prevalence of 
diabetes in epidemiological studies than women [3]. In 
addition, a lower socioeconomic status is strongly linked 
to an increased disease prevalence [4]. Gestational dia-
betes is a special form of diabetes mellitus caused by 
insulin resistance which generally recedes after preg-
nancy; however, women with this form of the disease 
have a significantly higher risk of developing type 2 dia-
betes mellitus in later life [5, 6]. Importantly, if diabetes 
goes undetected or remains inadequately treated, it can 
cause life-threatening metabolic imbalances. Chronically 
elevated blood glucose levels result in the damage of 
blood vessels and the peripheral nervous system [7]. As 
a consequence the risk of cardiovascular disease, renal 
dysfunction, retinal damage and diabetic foot syndrome 
is increased [8, 9]. In addition, diabetes also causes long-
term complications such as heart attacks, stroke, chronic 
kidney failure, blindness and amputations of the feet. 
Finally, pregnant women who have pre-existing diabetes 
or who develop diabetes during pregnancy have an 
increased risk of adverse pregnancy outcomes [10].
However, diabetes is not just linked to adverse effects 
for the individuals concerned, but also to costs to soci-
ety. On the one hand, these costs arise from the expenses 
incurred through treatment (direct costs) and, on the 
other hand, due to the aggregate loss of economic pro-
ductivity caused by sufferers’ incapacity to work and pre-
mature retirement (indirect costs). The German Federal 
Statistical Office estimates that the medical expenses 
accrued due to diabetes amounted to €6.3 billion in 2008 
alone [11]. Current estimates calculate the annual med-
ical expenses associated with diabetes as amounting to 
€16.1 billion [12]. Medical costs for people with diabetes 
are therefore between 1.7 and 1.8 times higher than for 
people without the disease [12-14].
In 1989, the St Vincent Declaration was adopted at 
the international level as a means of reducing the sec-
ondary health problems and premature mortality asso-
ciated with diabetes (see Info box 1). Efforts to improve 
the treatment of people with diabetes have also been 
undertaken at national level, with improvements to care 
Info box 1:  The goals of the St Vincent 
Declaration (1989) [45] 
  Reduce new diabetes-related blindness
by a third or more
  Reduce the frequency of diabetes-related
terminal kidney failure
  Reduce the number of amputations due
to diabetes-related gangrene by at least
one half
  Reduce morbidity and mortality due to
coronary heart disease in people with
diabetes via intensive programmes
aimed at reducing risk factors
  Normal pregnancy outcomes in diabetic
patients and a similar rate of complica-
tions to those found in non-diabetic
women
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being implemented at health-system level. Since the 
introduction of the National Disease Management 
Guidelines (NDMG) on type 2 diabetes mellitus in 2002, 
evidence-based support is available to help make deci-
sions on medical care; NDMG are continuously updated 
to reflect the latest research [15]. In 2003, the Disease 
Management Programmes (DMP) were first imple-
mented for type 2 diabetes mellitus and later on expanded 
to type 1. The aim of the DMP is to ensure that patient 
treatment is structured, and that treatment outcomes 
are reviewed in accordance with established therapy and 
quality objectives [16, 17]. Over the last few years, enrol-
ment in the DMP has steadily increased: in 2015, around 
4 million patients with diabetes mellitus were enrolled 
in the programmes [18]. In addition, in 2003, the national 
health goal ‘Type 2 diabetes mellitus: reduction of dis-
ease risk, early recognition and treatment of patients’ 
was adopted; it defined specific measures and led to the 
establishment of pilot schemes in health care practice 
[19]. Alongside scientific evidence from studies of care 
provision, trend analyses based on the RKI’s health data 
also suggest that the structural changes mentioned 
above have contributed towards an improved care of 
people with diabetes [20, 21].
The situation described above demonstrates that 
diverse data sources and information and numbers 
already exist to measure occurrence of diabetes and care. 
However, until now, Germany’s federalist and pluralist 
health system has measured diabetes using data 
obtained from different sources each with a specific 
research focus. As such, these analyses have been lim-
ited in scope, and were not necessarily even based on a 
sustainable data source. In addition, their findings are 
rarely comparable as they focus on a variety of time peri-
ods and define their indicators in different ways. This 
situation makes it difficult to provide timely, evi-
dence-based policy advice, which by contrast need reli-
able and comparable measures of the developments in 
diabetes and diabetes care.
Despite the fact that diabetes mellitus has high pub-
lic health relevance, a comprehensive and continuous 
analysis of the disease, its consequences, developments 
in risk and care and the potential for prevention, have 
not yet been established at the population level. This is 
due to the complex causes of the disease, but also 
because of the fragmented data collection being under-
taken and the fact that current data is usually tied to a 
specific purpose, as stated above. In addition, existing 
barriers to the use of secondary data (see info box 2) for 
research into scientific issues still need to be identified 
and dismantled.
In the coming years, the RKI intends to establish a 
form of sustainable diabetes surveillance that is in 
line with the approach adopted by the World Health 
Organization (WHO) on the prevention and control of 
non-communicable diseases [22] and the associated rec-
ommendations on establishing effective surveillance 
mechanisms. The aim is to develop a form of diabetes 
surveillance that can be applied to the surveillance of 
other non-communicable diseases (as part of Non-com-
municable Disease Surveillance, NCD). This involves 
expanding the RKI’s existing health monitoring mea sures 
and integrating current data sources into an overall 
approach to diabetes surveillance (see Figure 1).
Info box 2:  The definition of  
secondary data 
In contrast to primary data, secondary  
data are data that were not gathered for a 
pre-defined investigative or research inter-
est or that are analysed in a manner that is 
different from the original reason the data 
was collected. Boosted by the development 
of storage and computing capacities, in 
recent years, process-produced, and  
routinely-collected information has been 
harnessed increasingly for evaluations in 
health research. This also applies to data 
gathered from the contributions to and 
range of services provided by statutory 
health insurers. These developments have 
led the term ‘routine data’ to become  
synonymous with the more established 
term ‘secondary data’. A comprehensive  
overview of the issues associated with 
secon dary data can be found in the manual 
‘Routinedaten im Gesundheitswesen’ [46].
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Federal Health Monitoring at the  
Robert Koch Institute
Administrative and health claims data 
(e.g. social insurance data)
Regional cohort studies  
(e.g. KORA, SHIP)
Official statistics  
(e.g. mortality and hospital statistics)
Regional  
Disease Registers  
(heart attack,  
renal insufficiency)
Diabetes Register  
(e.g. children and adolescents, 
pregnancy)
National diabetes surveillance at the  
Robert Koch Institute
KORA = Cooperative health research in the Augsburg region (Kooperative Gesundheitsforschung in der Region Augsburg)
SHIP = Study of Health in Pomerania (Leben und Gesundheit in Vorpommern)
Fig. 1 
Data sources for national 
diabetes surveillance 
Source: own diagram
As is clear from info box 3, the development of health 
monitoring into a disease-specific form of surveillance 
means that, in addition to the recurring epidemiological 
description of the course of the disease and diabetes care, 
as derived from surveys based on interviews and exami-
nations, timely analyses can be produced using regularly 
available routine data. Combining the primary data that 
the RKI already collects with secondary data sources ena-
bles a reliable and continuous data pool to be made avail-
able to health-policy decision-makers. Moreover, prompt 
demonstrations can then be provided of the specific areas 
where action needs to be taken, which can be followed up 
by targeted public health measures [23].
2. Project planning
The research project at the RKI aimed at developing a 
system of diabetes surveillance was initiated in Decem-
ber 2015. It is to extend over a four-year period and is 
funded by the Federal Ministry of Health.
The project is divided into three overlapping phases:
Planning phase
   Review available data sources
   Define appropriate core indicators and gain a con-
sensus about them
   Develop a conceptual framework
Implementation phase 
   Establish standards for merging information from
different data sources
   Identify barriers to usage, and data gaps
   Conduct feasibility and comparative studies with
research partners on the use of existing data
sources
Product phase
   Develop a model for regular, focused reporting
   Analyse the sustainability of the underlying data
and the transferability of experiences and processes
to other chronic diseases
Info box 3:  Health monitoring and 
surveillance [47, 48] 
Health monitoring
  Periodically recurring collection and
analysis of health data at the population
level
  Comparable over time and internationally
  Scientific analyses and health monitoring
for politics and the public
Surveillance
  Intensified monitoring of health prob-
lems that require increased vigilance
  Systematic analyses and current inter-
pretations of continuously available
health data
  ‘Data for Action’: policy advice, accom-
panying and evaluation research, devel-
opment of measures
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From the planning phase to the beginning of the pro-
ject, the focus has been placed on the development of 
a conceptual framework, the selection of indicators that 
appropriately capture the situation of diabetes in Ger-
many, as well as an initial review of available data sources. 
The indicators need to reflect the evidence gained from 
indicators that have already been applied in the struc-
tured observation of diabetes mellitus in other countries 
[24-27] and international recommendations on the devel-
opment of sustainable indicators [28-31].
During the implementation phase, which started par-
allel to the planning phase, analyses are conducted of 
existing data sources together with project partners to 
identify the ways in which the chosen indicators can be 
measured and to determine barriers to data usage and 
any remaining data gaps. During this phase, the RKI also 
examines how the health care data from the German 
statuatory health insurance funds (which is provided by 
the German Institute of Medical Documentation and 
Information – DIMDI) [32] can be continually integrated 
into diabetes surveillance.
During the product phase until the end of the project, 
a model form of focused diabetes reporting that is prop-
erly geared towards the target group is to be established 
as part of health reporting. The goal is to provide regu-
lar information to stakeholders in health policy, the pub-
lic and science in the form of standardised analyses 
based on the indicators defined in the project about 
developments in diabetes in Germany.
An interdisciplinary project advisory board, which 
began its work in September 2016, accompanies project 
implementation [33]. The Scientific Advisory Board usually 
meets twice a year as part of a common board meeting.
Diabetes surveillance is also intended to provide 
a forum for international scientists and diabetes re-
searchers from Germany, as well as patient representa-
tives and health policy stakeholders to meet at confer-
ences and workshops. On the one hand, the aim is to 
promote learning and knowledge transfer that can be 
incorporated into diabetes surveillance, but it is also 
aimed at improving networking between the people and 
institutions involved.
Reduce the risk of diabetes
  Prevalence of risk factors linked to behaviour or specific conditions and resources; incidence of diabetes
Improve early diagnosis and treatment
  Prevalence of known/undetected diabetes; structure, process and outcome quality indicators
Reduce the complications caused by diabetes
  Frequency of long-term effects, mortality (the St Vincent goals)
Reduce the burden and costs of the illness
  Direct/indirect costs; the number of years spent ill/healthy
Fig. 2 
Relevant fields of action for the development 
of indicators in diabetes surveillance 
Source: own diagram 
The aim of the diabetes  
surveillance is to provide a 
sustainable data-driven  
decision-making basis with 
which to make public health 
policy-decisions that acts as 
 a model for the surveillance 
of other non-communicable 
diseases.
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3. Current status
3.1  Developing a conceptual framework and defining
core indicators
Four fields of action were defined in line with the health 
objective ‘Type 2 diabetes mellitus’ (which was adopted 
in 2003) and the Health Care Quality Indicators’ frame-
work [34] developed by the Organisation for Economic 
Co-operation and Development (OECD). These fields 
were then assigned relevant concepts for the develop-
ment of related indicators (see Figure 2).
The first step towards defining a set of core indicators 
involved a review of internationally established surveil-
lance systems and diabetes registers. The review focused 
on the specifics of German health care and the German 
health care system. Potential single indicators were also 
compiled in parallel using a systematic literature study 
undertaken by the Institute for Applied Quality Improve-
ment and Research in Health Care (AQUA). In a second 
step, an international expert workshop on indicator 
development took place in Berlin [35]; this was conducted 
after a structured review of indicators that had already 
been applied in research. The feedback from the expert 
panel was prepared both qualitatively and quantitatively 
and provided to the advisory board. In order to gain con-
sensus on a core set of indicators, the indicators iden-
tified in this process will be evaluated in terms of rele-
vance and feasibility using the Delphi method [36, 37].
It is unlikely that it will be possible to measure all 
indicators properly at the beginning of a study using 
existing data sources. Therefore, in addition to quality 
criteria, public health relevance, validity, clarity, sensitiv-
ity to change, comparability and health policy adaptabil-
ity [30], data availability also represents an important 
criterion in the selection of indicators. Relevant indica-
tors that cannot be properly captured using existing data 
sources are to be integrated into diabetes surveillance 
as part of a later step (see Figure 3).
The process of consensus used to select core indica-
tors is to be completed in the first half of 2017, with the 
framework for diabetes surveillance due to be published 
soon afterwards. 
Until now, very little data has existed for Germany on 
self-reported impairments, disease-specific knowledge 
and the informational needs of the people suffering from 
diabetes. For this reason, the RKI, in close cooperation 
Indicators from the 
health monitoring 







































 are or will be available in other data sources
Fig. 3 
A schematic representation of the gradual 
extension of the indicator set in accordance 
with data availability 
Source: own diagram 
Until now, a coordinated set 
of indicators is missing that 
could enable an expanded 
form of health monitoring 
(surveillance) to be conducted 
using suitable data sources.
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with the Federal Centre for Health Education (BZgA), 
intends to conduct a separate nationally representative 
telephone survey of adults aged 18 and over on these 
issues. The survey’s findings are to be incorporated into 
an information and communication strategy being 
planned by the BZgA.
3.2  Conferences and workshops
The conceptual development of diabetes surveillance is 
supported by an intensive professional exchange con-
ducted during expert workshops and specialist confer-
ences that are regularly held during the duration of the 
project.
   Diabetes Register Conferences, in cooperation with 
the German Diabetes Association (DDG) and diabe-
tesDE – German Diabetes Hilfe (launch event in Ber-
lin, 22 April 2015)
 ▹ Definition of what is required of a national dia betes 
register/diabetes surveillance
 ▹ Possibilities and prospects of integrating diabetes 
registry data into a system of national diabetes sur-
veillance
 ▹ Aims, data availability and data quality of diabetes 
surveillance in Germany
   Talks between the Federal (Federal Ministry of Health) 
and federal state level (launch event in Berlin, 22 July 
2015)
 ▹ Coordination and cooperation with the federal 
states during regular workshops at the level of the 
Permanent Working Group of the Highest State 
Health Authorities (AOLG), AG Health Monitoring 
 ▹ Regionalisation of diabetes reporting
   National expert workshops on the use of secondary 
data (launch event in Berlin, 7 December 2015)
 ▹ The use of  health care data from the German Insti-
tute of Medical Documentation and Information 
(DIMDI) based on the Data Transparency Regula-
tions (DaTraV)
 ▹ Integration, consolidation and use of additional 
secondary data sources in diabetes surveillance
   International expert workshops (launch event in 
Berlin, 11 July 2016) [35]
 ▹ Development and international comparability of 
indicator-based surveillance systems in Germany
 ▹ Best practice models for a national diabetes report
3.3 Review of data availability and usability
A key result of the diabetes register conferences listed 
above was that four methods projects on the use of sec-
ondary and registry data were initiated together 
with universities and other scientific institutions 
(see Table 1). The aim of these collaborations is to ana-
lyse the suitability of existing data sources for incorpo-
A diabetes surveillance 
system covering Germany  
is being established at the 
Robert Koch Institute in  
close cooperation with  
stakeholders from science, 
care, health service  
self-administration and health 
policy.
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The harmonisation and correlation of register data
Project aims   Prevalence estimates of type 1 diabetes in adults
  Prevalence estimates of type 2 diabetes in adolescents (11-17 years)
Data source(s)   Child Diabetes Register DIARY (Diabetes Incidence Registry)
  Diabetes Register North Rhine-Westphalia
  Saxony’s Diabetes Register
  Diabetes Patients Progress Documentation (DPV-Register)
Project partners   University of Ulm
  University of Tübingen
  Technical University Dresden
  German Diabetes Centre (DDZ), Düsseldorf
Measuring the quality of care using routine data
Project aims   Definition of core indicators measuring care quality
  Determination of a minimum data set
Data source(s)   Routine data from AOK (a large statuatory health insurance company) Baden-Württemberg
Project partners   University of Heidelberg
  Institute for Applied Quality Improvement and Research in Health Care (AQUA) Göttingen
Expansion of data on quality of care in cases of gestational diabetes
Project aims   Expansion of the gestational diabetes register and the development of a pilot region (North Rhine)
  Analysis of the quality of care provided to women with gestational diabetes
  Analysis of gestational diabetes screening
Data source(s)   Gestational diabetes register (GestDiab)
Project partners   Scientific Institute of established Diabetologists (winDiab)
Surveillance of potentially avoidable hospital admissions (AHA) in cases of diabetes mellitus
Project aims   Definition of relevant indicators for analysis of AHA in cases of diabetes mellitus
  Calculation of population-based rates of AHA
  Setting up of a time series 2005-2014
Data source(s)   Statistics on Diagnosis Related Groups (DRG) (Federal Statistical Office)
Project partners   Hochschule Niederrhein
Table 1 
Projects for the use of available 
data sources in diabetes surveillance
ration into diabetes surveillance and to close data 
gaps.
The projects presented here can be expected to pro-
vide important insights and indicators into develop-
ments in diabetes and diabetes care. For example, due 
to the low prevalence of type 1 diabetes and type 2 dia-
betes in children and adolescents, the RKI’s health sur-
veys cannot provide any nationally representative find-
ings on either form of the disease. In the future, these 
data gaps are to be closed by integrating data from the 
four existing registers covering type 1 diabetes in chil-
dren and adolescents in Germany. In particular, the 
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nationwide Diabetes Patient History Register (DPV) is 
focused on the continued observation of young patients 
into early adulthood and on the analysis of health care 
needs and the quality of care provision. Another project 
will provide data on gestational diabetes screening 
(which has been stipulated by law since 2015) and, thus, 
help improve the care of women with this form of the 
disease. Furthermore, potentially avoidable hospital 
admissions (AHA), in other words hospitalisations that 
could be avoided if care were better coordinated, con-
stitute an important quality indicator of outpatient care, 
especially in the case of diabetes [38]. Moreover, in addi-
tion to survey and register data, increased use of sec-
ondary data sources is needed, in particular in order to 
be able to better represent aspects that are relevant to 
care using indicators of structural, process and outcome 
quality. To this end, the methods projects are develop-
ing suggestions as to which indicators can be repre-
sented using routine data from statutory health insurers 
and how this process can be better consolidated.
In the coming years, projects are also planned in 
cooperation with scientific project partners. The choice 
of projects depends on established criteria aimed at 
ensuring that their analyses and results can be integrated 
into diabetes surveillance.
4. Discussion
Unlike in some other countries, there is no continuous 
analyses or reporting aimed to summarize developments 
in diabetes mellitus or its associated health care provi-
sion being conducted in Germany. Data from other coun-
tries with an established surveillance system, such as 
the United States, have shown that active and system-
atic monitoring of developments in the disease have 
significantly reduced diabetes- and cardiovascular-relat-
ed hospitalisations, in particular. Furthermore, appro-
priate preventive measures have also reduced the pro-
portion of diabetes-related eye diseases and the rate of 
new occurrences of kidney disease [9, 39, 40]. Smaller 
countries with established disease registers, such as 
Denmark, Sweden and Scotland, have also noted 
improvements in diabetic care [41-43]. Although similar 
trends have been observed for Germany [20], the feder-
al structure of the German healthcare system means that 
it has been difficult to develop a continuous and com-
parable analysis of health care provision over time.
The implementation of an indicator-based system of 
diabetes surveillance in Germany would finally make it 
possible to conduct comparative summarising analyses 
of the dynamics of diabetes as well as disease preven-
tion and care provision over time. By developing a form 
of systematic diabetes surveillance, we can expect care 
structures and treatment approaches to be regularly eval-
uated in the future; this will make it possible to gauge 
the benefits they provide. Moreover, diabetes surveil-
lance will also provide health policy-makers with evi-
dence-based data that can be used to make decisions 
about the targeted allocation of funding aimed at improv-
ing care and diabetes prevention. However, in this regard, 
it is crucial that surveillance and health monitoring is 
geared towards the target group and that various dis-
ease prevention and care needs can be differentiated 
between so they can be represented according to 
Due to the high disease 
frequency and the burden 
caused by diabetes,  
continuous observation and 
analysis of developments 
associated with the disease 
and its care are needed.
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socio-demographic and regional aspects over time. This 
is the only way of ensuring that health policy can provide 
a targeted and evidence-based response. This applies 
as much to primary preventive measures aimed at reduc-
ing the risk of diabetes as to secondary and tertiary pre-
vention strategies aimed at improving diagnosis and 
treatment in order to prevent long-term complications. 
Close and continuous cooperation between epidemiol-
ogy and care, as well as strong networking with health 
policy-makers, are of essential importance if the results 
of diabetes surveillance are to be of practical use. The 
experience gained outside of Germany demonstrates 
that the success of surveillance is dependent on the fol-
lowing factors:
   Agreement between all stakeholders from research,
health practice and health policy about common goals
and the consequences of action
   The application of defined quality criteria in the selec-
tion of indicators
  The possibility of developing stratified analyses that
take into account socio-demographic and regional
differences 
As stated in the introduction, it is highly likely that 
adults with diabetes mellitus will develop other chronic 
diseases (co-morbidities). However, the majority of 
concomitant diseases and complications are linked to 
lifestyle-related risk factors such as obesity, a lack of 
physical activity and smoking. Therefore, diabetes sur-
veillance needs to deploy a data pool and indicators 
that are relevant for the study of other non-communi-
cable diseases. In Canada, it has been shown that dia-
betes surveillance can serve as a model for the surveil-
lance of other chronic non-communicable diseases [44], 
as is recommended by the World Health Organization 
[22].
5. Conclusion
The implementation of diabetes surveillance should lead 
to the creation of a comprehensive and reliable data set 
for health-policy decision-making. Only when develop-
ments in the disease and diabetes care are systemati-
cally, periodically and regularly monitored and analysed, 
appropriate measures aimed at reducing the risk of dia-
betes and improving treatment can be evaluated and 
adapted. Improving the regional and sub-regional data 
pool and regionalised health monitoring is of particular 
importance here. In addition to providing policy advice, 
it is important to guarantee that information is made 
available to the public in a timely and continuous man-
ner in cooperation with the German Federal Centre for 
Health Education. In the future, the surveillance of dia-
betes mellitus is to be used as a model with which to 
develop a similar system for other non-communicable 
diseases; this process will also involve striving for close 
international cooperation.
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